All In Biotech

Drug Trial Radar · NCT01203917

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,060

Actual

Start

Sep 2010

Primary completion

Aug 2012

Study completion Jun 2016

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 17, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is carried out to see how Caucasian patients with lung cancer which has EGFR mutation will respond to gefitinib (IRESSA™) as a first line treatment. Safety data will also be collected and analysed to confirm that treatment with gefitinib is safe and well tolerated.

Conditions

  • Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Interventions

  • GefitinibDrug

    250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) (Investigator)Time frame: Scans taken at baseline and then follow up assessments taken every 6 weeks until progression, or last evaluable assessment in the absence of progression, assessed up to 23 months

Locations

61 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Stara Zagora, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Vratsa, Bulgaria

  • Research Site

    Angers, France

  • Research Site

    Saint-Herblain, France

  • Research Site

    Athens, Greece

  • Research Site

    Heraklion, Greece

  • Research Site

    Larissa, Greece

  • Research Site

    Thessaloniki, Greece

  • Research Site

    Budapest, Hungary

  • Research Site

    Deszk, Hungary

  • Research Site

    Edelény, Hungary

  • Research Site

    Győr, Hungary

  • Research Site

    Mosdós, Hungary

  • Research Site

    Székesfehérvár, Hungary

  • Research Site

    Ancona, Italy

  • Research Site

    Carpi, Italy

  • Research Site

    Livorno, Italy

  • Research Site

    Perugia, Italy

  • Research Site

    Oslo, Norway

  • Research Site

    Stavanger, Norway

  • Research Site

    Trondheim, Norway

  • Research Site

    Gdansk, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Lubin, Poland

  • Research Site

    Olsztyn, Poland

  • Research Site

    Otwock, Poland

  • Research Site

    Szczecin, Poland

  • Research Site

    Torun, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Wroclaw, Poland

  • Research Site

    Coimbra, Portugal

  • Research Site

    Lisbon, Portugal

  • Research Site

    Porto, Portugal

  • Research Site

    Vila Nova de Gaia, Portugal

  • Research Site

    Brasov, Romania

  • Research Site

    Bucharest, Romania

  • Research Site

    Cluj-Napoca, Romania

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.